Ms. Jennifer Fox's most recent trade in Myriad Genetics, Inc. was a trade of 4,398 Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on Sept. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics Inc | Ms. Jennifer Fox | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.23 per share. | 03 Sep 2026 | 4,398 | 305,964 (0%) | 0% | 3.2 | 14,206 | Common Stock |
| Zenas Biopharma Inc | Ms. Jennifer A. Fox | See Remarks | 15 Jun 2026 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | ||
| Zenas Biopharma Inc | Ms. Jennifer A. Fox | See Remarks | Grant, award, or other acquisition of securities at price $ 13.35 per share. | 15 Jun 2026 | 1,592 | 1,592 | - | 13.3 | 21,253 | Common Stock |
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 28 May 2026 | 135,000 | 135,000 | - | - | Director stock option (right to buy) | ||
| Myriad Genetics Inc | Ms. Jennifer Fox | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 195,876 | 316,357 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics Inc | Ms. Jennifer Fox | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.66 per share. | 12 Mar 2026 | 5,995 | 310,362 (0%) | 0% | 4.7 | 27,937 | Common Stock |
| Myriad Genetics Inc | Ms. Jennifer Fox | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.80 per share. | 03 Sep 2025 | 4,435 | 120,481 (0%) | 0% | 6.8 | 30,158 | Common Stock |
| Zenas Biopharma Inc | Ms. Jennifer A. Fox | See Remarks | 10 Jun 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | ||
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 29 May 2025 | 125,862 | 125,862 | - | - | Director stock option (right to buy) | ||
| Myriad Genetics Inc | Ms. Jennifer Fox | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 63,145 | 124,916 (0%) | 0% | 0 | Common Stock | |
| Zenas Biopharma Inc | Ms. Jennifer A. Fox | See Remarks | 16 Dec 2024 | 8,125 | 8,125 | - | - | Stock Option (Right to Buy) | ||
| Zenas Biopharma Inc | Ms. Jennifer A. Fox | See Remarks | 12 Sep 2024 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | ||
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 03 Sep 2024 | 9,535 | 9,535 | - | - | Director stock option (right to buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2024 | 15,000 | 186,382 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.19 per share. | 08 Jun 2024 | 2,376 | 171,382 (0%) | 0% | 6.2 | 14,707 | Common Stock |
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 30 May 2024 | 62,558 | 62,558 | - | - | Director stock option (right to buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | 13 Mar 2024 | 125,000 | 223,169 | - | - | Employee Stock Options (Right to Buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.23 per share. | 29 Feb 2024 | 4,103 | 174,461 (0%) | 0% | 3.2 | 13,253 | Common Stock |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.39 per share. | 29 Feb 2024 | 703 | 173,758 (0%) | 0% | 3.4 | 2,383 | Common Stock |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.74 per share. | 23 Feb 2024 | 229 | 178,564 (0%) | 0% | 2.7 | 627 | Common Stock |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.00 per share. | 11 Nov 2023 | 413 | 178,793 (0%) | 0% | 2 | 826 | Common Stock |
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 12 Jul 2023 | 46,632 | 46,632 | - | - | Director stock option (right to buy) | ||
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 12 Jul 2023 | 42,515 | 42,515 | - | - | Director stock option (right to buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | 09 Jun 2023 | 49,231 | 98,169 | - | - | Employee Stock Option (Right to buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 49,231 | 179,206 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 24,616 | 129,975 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 12,308 | 105,359 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | 02 Mar 2023 | 12,308 | 48,938 | - | - | Employee Stock Options (Right to Buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 6,154 | 93,051 (0%) | 0% | 0 | Common Stock | |
| Nuvation Bio Inc (Class A) | Ms. Jennifer A. Fox | Chief Financial Officer | 28 Feb 2023 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.38 per share. | 28 Feb 2023 | 1,005 | 86,897 (0%) | 0% | 12.4 | 12,442 | Common Stock |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.71 per share. | 23 Feb 2023 | 258 | 87,902 (0%) | 0% | 13.7 | 3,537 | Common Stock |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.30 per share. | 23 Feb 2023 | 231 | 88,160 (0%) | 0% | 14.3 | 3,303 | Common Stock |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 42,135 | 88,391 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 14,045 | 46,256 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.00 per share. | 11 Nov 2022 | 416 | 32,211 (0%) | 0% | 15 | 6,240 | Common Stock |
| ProKidney Corp Ordinary | Ms. Jennifer A. Fox | Director | 20 Sep 2022 | 129,370 | 129,370 | - | - | Stock option (right to buy) | ||
| Nuvation Bio Inc (Class A) | Ms. Jennifer A. Fox | Chief Financial Officer | 29 Aug 2022 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | 01 Mar 2022 | 26,584 | 26,584 | - | - | Employee Stock Options (Right to Buy) | ||
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 17,794 | 32,627 (0%) | 0% | 0 | Common Stock | |
| Emergent Biosolutions Inc | Ms. Jennifer Fox | EVP, Ext Aff, GC, Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 7,583 | 14,833 (0%) | 0% | 0 | Common Stock | |
| Nuvation Bio Inc (Class A) | Ms. Jennifer A. Fox | Chief Financial Officer | 28 Feb 2022 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) |